Compare Altria Group Inc (MO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Viatris Inc — how do they compare? Altria Group Inc trades at $71.68 (market cap $119.25B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Altria Group Inc is far larger — about 6× Viatris Inc's market cap, and Altria Group Inc pays the higher dividend (6.22%). Which is the better fit depends on your goals — on Pluang, investors hold Altria Group Inc for 154 Days and Viatris Inc for 57 Days on average.
| MO | VTRS | |
|---|---|---|
Market Cap | $119.25B | $20.03B |
Volume | 11,178,169 | 14,109,977 |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $18.27 |
52-Week Low | $54.72 | $9.74 |
Typical Hold Time | 154 Days | 57 Days |
Enterprise Value | $141.46B | $32.15B |
Dividend Yield | 6.22% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $71.43, up 2.95% with a bullish technical signal and strong cash flow generation. The stock shows mixed earnings performance with two misses and one beat in recent quarters, while maintaining a 39% net income margin and $9.3B operating cash flow. Recent news highlights the company's 6.6% dividend yield and 60 consecutive annual increases, though some analysts express concerns about negative equity and regulatory challenges.
MO presents a compelling income opportunity with its high dividend yield and consistent payout history, but faces headwinds from declining cigarette volumes and regulatory uncertainty. The stock trades below analyst consensus target of $69.71, offering potential upside if the company successfully navigates its smoke-free transition. Key risks include negative shareholder equity and margin pressure from shifting consumer preferences.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
